Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexapotide triflutate in low risk localized prostate cancer
NCT01620515Phase 2Completed
- Sponsor
- Nymox Pharmaceutical
- Start
- Feb 2012
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of fexapotide triflutate in prostate cancer (PCa), sponsored by Nymox Pharmaceutical. Started Feb 2012; status: completed.
02
Drugs
fexapotide triflutate
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01620515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01620515.